Epsilogen is the leading developer of novel IgE antibodies for the treatment of cancer London, 16 February 2021 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, notes that IgEs and...
February 16, 2021 - Press Releases